Alphamab Oncology

Overview

Alphamab Oncology (Alphamab) is a clinical-stage biopharmaceutical company that discovers, develops, manufactures and commercializes therapeutics for treatment of cancer. Its pipeline products include KN035, an injectable PD-L1 inhibitor for the treatment of dMMR/MSI-H solid tumors; KN046, a BsAb immune checkpoint inhibitor; KN026, an anti-HER2 bispecific antibody; and KN019, a CTLA-4-based immunosuppressant fusion protein drug candidate used for treating indications such as autoimmune diseases, and induced immune disorders. The compnay developed its proprietary CRIB and CRAM platforms for bispecific and protein engineering and antibody screening to develop best-in-class medicines in oncology. Alphamab is headquartered in Suzhou, Jiangsu, China.
Key Stats
Address
218 XingHu Street, Suzhou Industrial Park, Bldg. C23, Suzhou, Jiangsu
Headquarters

China

Contact

86 512 62850800

No of Employees

334

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

9966 [HKG]

Net Income (2020)

$-62 m

48.6% (2020 vs 2019)
Market Cap *

$2,703 m

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Alphamab OncologyLuye Pharma Group Ltd
Key Information
Headquarters China China
Headquarter City Suzhou YANTAI
Headquarter State/Province Jiangsu Shandong
No. of Employees 334 4,963
Entity Type Public Public

Products & Services

Alphamab is a clinical-stage biopharmaceutical company based in China. Key products of the company include the following:

Products
  • Pipeline Products
  • KN035
  • KN046
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Contracts/Agreements In June, the company and Sanofi entered into an agreement to investigate the combination of…
2020 Contracts/Agreements In May, the company's subsidiary, Jiangsu Alphamab Biopharmaceuticals entered into a partnership with Sunshine Lake…
2019 Stock Listings/IPO In July, the company announced its plans to raise IPO of shares.
2019 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


AlphaMab Co Ltd

Address

218 XingHu Street, Suzhou Industrial Park, Suzhou
China

Telephone

86 512 65951826

Website

www.alphamab.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
23 Aug 2021 Shanghai JMT-BIO Technology Enters into Licensing Agreement with Jiangsu Alphamab Oncology Licensing Agreement Shanghai Jin Fremantle Biotechnology Co Ltd Alphamab Oncology
12 Jun 2020 Alphamab Oncology Raises USD30.8 Million in Private Placement of Shares Equity Offering Alphamab Oncology
20 Dec 2019 TRACON Pharma, 3D Medicines and Jiangsu Alphamab Biopharma Enter into Development Partnership Partnership TRACON Pharmaceuticals Inc; 3D Medicines Inc; Alphamab Oncology
15 Jul 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
28 May 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
08 Mar 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

36

Active Jobs

0

Posted

0

Closed

Job Trends

Latest Jobs

Job title Company Country
Specialist, Quality system Alphamab Oncology China
Engineer, Cell Culture Alphamab Oncology China
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar